Recruiting NCT05509933
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Budesonide.
- Who it may be relevant to
- Registry conditions: Engraftment Syndrome. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
Interventions
- Drug Budesonide
budesonide starting day 5 after transplant
Primary outcome measures
- non-infectious fever [Time frame: 30 days post stem cell transplant]
Eligibility criteria
Inclusion criteria
- • Patients 18-80 years of age with a diagnosis of a hematological malignancy
- Meet the BMT program criteria to undergo hematopoietic stem cell transplantation for hematologi malignancies
Exclusion criteria
- • Patients enrolled in investigational clinical trials
- Sct for non hematologic malignancies
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
United States · 1 center
- Henry Ford Health System — Detroit
Identifiers
NCT: NCT05509933 · 15795